Recombinant Granulocyte Colony-Stimulating Factor

BIOLOGICAL11 trials

Sponsors

Fred Hutchinson Cancer Center, University of Washington, City of Hope Medical Center, Emory University, National Cancer Institute (NCI)

Conditions

Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Leukemia of Ambiguous LineageAcute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia in RemissionAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia in Remission

Phase 1

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

CompletedNCT03531918

Fred Hutchinson Cancer CenterAcute Myeloid Leukemia

Start: 2018-09-14End: 2021-11-01Updated: 2023-08-30

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

RecruitingNCT03670966

Fred Hutchinson Cancer CenterAcute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission +9

Start: 2019-07-10End: 2029-10-20Target: 30Updated: 2026-06-22

Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms

TerminatedNCT04196010

University of WashingtonMyeloid Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

Start: 2020-05-08End: 2021-10-13Updated: 2023-12-28

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

RecruitingNCT04797767

University of WashingtonAcute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia +10

Start: 2022-02-04End: 2028-12-31Target: 62Updated: 2026-04-17

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

RecruitingNCT07020533

City of Hope Medical CenterAccelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia +9

Start: 2026-05-08End: 2029-05-30Target: 46Updated: 2026-07-08

Phase 2

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

CompletedNCT04195945

Fred Hutchinson Cancer CenterAcute Myeloid Leukemia, Myeloid Neoplasm

Start: 2020-05-27End: 2026-05-20Updated: 2026-06-29

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

RecruitingNCT04370301

Fred Hutchinson Cancer CenterPrimary Myelofibrosis, Secondary Myelofibrosis

Start: 2021-02-09End: 2029-08-31Target: 20Updated: 2026-01-12

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

RecruitingNCT04871607

City of Hope Medical CenterRecurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma

Start: 2021-11-02End: 2029-10-02Target: 33Updated: 2025-12-04

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

RecruitingNCT07046078

Fred Hutchinson Cancer CenterAcute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia +1

Start: 2025-09-26End: 2029-06-30Target: 20Updated: 2026-01-30

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

Not yet recruitingNCT07605416

National Cancer Institute (NCI)Plasma Cell Leukemia

Start: 2026-07-29End: 2032-11-06Target: 74Updated: 2026-07-06

Phase 4

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

RecruitingNCT07101445

Emory UniversityMultiple Myeloma

Start: 2025-09-24End: 2027-12-31Target: 94Updated: 2026-07-06

Related Papers

Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms.

2026-07-13

A randomized phase 2 trial of CPX-351 vs. CLAG-m (Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone) in medically less-fit adults with previously untreated acute myeloid leukemia (AML) or other high-grade myeloid neoplasms

Blood2025-11-03

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm.

2025-03-03

Phase I Trial Combining Venetoclax with Cladribine, Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) for Patients with Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms

Blood2024-11-05

Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Cancers2022-06-145 citations

A Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Blood2021-11-051 citations

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma

Blood Advances2021-10-1713 citations

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Blood2019-11-131 citations